Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl A Merrick

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Plos Genetics|August 29, 2012
Chemical genetics reveals a specific requirement for Cdk2 activity in the DNA damage response and identifies Nbs1 as a Cdk2 substrate in human cellsLara Wohlbold, Karl A Merrick, Saurav De, et al.
Cancer Cell|November 26, 2015
A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to ChemotherapyIan G Cannell, Karl A Merrick, Sandra Morandell, et al.
Biorxiv : the Preprint Server for Biology|May 10, 2023
An RNA Damage Response Network Mediates the Lethality of 5-FU in Clinically Relevant Tumor TypesJung-Kuei Chen, Karl A Merrick, Yi Wen Kong, et al.
Cell Reports. Medicine|October 8, 2024
An RNA damage response network mediates the lethality of 5-FU in colorectal cancerJung-Kuei Chen, Karl A Merrick, Yi Wen Kong, et al.
Bioorganic & Medicinal Chemistry Letters|July 17, 2019
Design of a brain-penetrant CDK4/6 inhibitor for glioblastomaSarah M Bronner, Karl A Merrick, Jeremy Murray, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Plos Genetics|August 29, 2012
Chemical genetics reveals a specific requirement for Cdk2 activity in the DNA damage response and identifies Nbs1 as a Cdk2 substrate in human cellsLara Wohlbold, Karl A Merrick, Saurav De, et al.
Cancer Cell|November 26, 2015
A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to ChemotherapyIan G Cannell, Karl A Merrick, Sandra Morandell, et al.
Biorxiv : the Preprint Server for Biology|May 10, 2023
An RNA Damage Response Network Mediates the Lethality of 5-FU in Clinically Relevant Tumor TypesJung-Kuei Chen, Karl A Merrick, Yi Wen Kong, et al.
Cell Reports. Medicine|October 8, 2024
An RNA damage response network mediates the lethality of 5-FU in colorectal cancerJung-Kuei Chen, Karl A Merrick, Yi Wen Kong, et al.
Bioorganic & Medicinal Chemistry Letters|July 17, 2019
Design of a brain-penetrant CDK4/6 inhibitor for glioblastomaSarah M Bronner, Karl A Merrick, Jeremy Murray, et al.
Pageof 2